ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,672.95
-0.08%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Eyetech Pharmaceuticals (MM) (EYET)

  7. Eyetech Pharmaceuticals (MM) (EYET) News

Eyetech (EYET)

Eyetech Pharmaceuticals (MM)
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EYET
DateTimeSourceHeadlineSymbolCompany
12/11/200522:52Business WireOSI Pharmaceuticals and Eyetech Pharmaceuticals Confirm November 14th ClosingNASDAQ:EYETEyetech Pharmaceuticals (MM)
10/11/200516:30PR Newswire (US)Eyetech Provides Update on Status of Pending Acquisition by OSI PharmaceuticalsNASDAQ:EYETEyetech Pharmaceuticals (MM)
31/10/200522:00PR Newswire (US)Eyetech Reports Third Quarter 2005 Financial ResultsNASDAQ:EYETEyetech Pharmaceuticals (MM)
17/10/200514:30PR Newswire (US)Eyetech Announces Enrollment of the First Patient in a Phase 3 Clinical Trial of Macugen(R) (pegaptanib sodium injection) in DiaNASDAQ:EYETEyetech Pharmaceuticals (MM)
05/10/200514:30PR Newswire (US)Recent Analyses Suggest That Treatment With Macugen(R) (pegaptanib sodium injection) May Provide Better Results for Patients WitNASDAQ:EYETEyetech Pharmaceuticals (MM)
16/09/200514:15PR Newswire (US)Macugen(R) (pegaptanib sodium injection) Receives Positive Opinion for Treatment of Neovascular Age-Related Macular DegenerationNASDAQ:EYETEyetech Pharmaceuticals (MM)
22/08/200501:48PR Newswire (US)OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger AgreementNASDAQ:EYET
22/08/200500:45Business WireOSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement; Acquisition Projected to be AccNASDAQ:EYETEyetech Pharmaceuticals (MM)
09/08/200514:30PR Newswire (US)Macugen(R) (pegaptanib sodium injection) Named Innovative Pharmaceutical Product Of The Year At The 2005 Pharmaceutical AchievemNASDAQ:EYETEyetech Pharmaceuticals (MM)
27/07/200522:30PR Newswire (US)Eyetech Reports Second Quarter 2005 Financial ResultsNASDAQ:EYETEyetech Pharmaceuticals (MM)
18/07/200519:30PR Newswire (US)Eyetech and Pfizer Comment on Data Presented at Meeting of Retinal SpecialistsNASDAQ:EYET
15/07/200518:30PR Newswire (US)Eyetech To Announce Second Quarter 2005 Financial Results On July 27, 2005NASDAQ:EYETEyetech Pharmaceuticals (MM)
22/06/200513:30PR Newswire (US)Eyetech Raises Full-Year Sales Forecast for Macugen(R) (pegaptanib sodium injection)NASDAQ:EYETEyetech Pharmaceuticals (MM)
21/06/200520:33PR Newswire (US)Eyetech Vision Day to Preview Future of Macugen FranchiseNASDAQ:EYET
14/06/200500:34PR Newswire (US)Eyetech to Host Vision Day on Wednesday, June 22NASDAQ:EYETEyetech Pharmaceuticals (MM)
10/06/200522:29Business WireSchaeffer's Midday Options Update Features General Motors, Citigroup, Northrop Grumman, Intel, and Eyetech PharmaceuticalsNASDAQ:EYETEyetech Pharmaceuticals (MM)
10/06/200513:31PR Newswire (US)Eyetech Announces Appointment of Henry Simon as Chairman of the Board and Resignation of John McLaughlinNASDAQ:EYETEyetech Pharmaceuticals (MM)
09/06/200513:30PR Newswire (US)Eyetech Adopts Stockholder Rights AgreementNASDAQ:EYETEyetech Pharmaceuticals (MM)
25/05/200502:30PR Newswire (US)Eyetech Announces Conference Call to Reiterate Confidence in Macugen(R) (Pegaptanib Sodium Injection)NASDAQ:EYETEyetech Pharmaceuticals (MM)
24/05/200513:30PR Newswire (US)Eyetech Announces Approval of Macugen(R) in Brazil for the Treatment of Neovascular (Wet) Age-Related Macular DegenerationNASDAQ:EYETEyetech Pharmaceuticals (MM)
10/05/200523:30PR Newswire (US)Eyetech to Present at the 2005 UBS Global Pharmaceuticals ConferenceNASDAQ:EYETEyetech Pharmaceuticals (MM)
05/05/200522:10PR Newswire (US)Eyetech Announces Approval of Macugen(R) in Canada for The Treatment of Neovascular (Wet) Age Related Macular DegenerationNASDAQ:EYETEyetech Pharmaceuticals (MM)
05/05/200515:19PR Newswire (US)Macugen(R) (pegaptanib sodium injection) Studied in Treatment of Diabetic Macular Edema (DME) and Other Diabetic Retinopathy LesNASDAQ:EYETEyetech Pharmaceuticals (MM)
02/05/200522:10PR Newswire (US)Preclinical Study Demonstrates Significance of VEGF164 in Pathological NeovascularizationNASDAQ:EYETEyetech Pharmaceuticals (MM)
02/05/200522:10PR Newswire (US)Safety Profile of Macugen(R) (pegaptanib sodium injection) in the Treatment of Neovascular Age-Related Macular Degeneration (AMDNASDAQ:EYETEyetech Pharmaceuticals (MM)
21/04/200522:30PR Newswire (US)Eyetech to Present at Morgan Stanley's Third Annual Global Healthcare Unplugged ConferenceNASDAQ:EYETEyetech Pharmaceuticals (MM)
20/04/200523:09PR Newswire (US)Eyetech Reports First Quarter 2005 Financial ResultsNASDAQ:EYETEyetech Pharmaceuticals (MM)
07/04/200522:30PR Newswire (US)Eyetech Announces Co-Founder Marty Glick Steps Down From Board To Act As ConsultantNASDAQ:EYETEyetech Pharmaceuticals (MM)
07/04/200522:30PR Newswire (US)Eyetech to Announce First Quarter 2005 Financial Results on April 20, 2005NASDAQ:EYETEyetech Pharmaceuticals (MM)
18/03/200521:15PR Newswire (US)Eyetech to Present at the Eighth Annual Lehman Brothers Global Healthcare ConferenceNASDAQ:EYETEyetech Pharmaceuticals (MM)
 Showing the most relevant articles for your search:NASDAQ:EYET

Your Recent History

BIT
P1YT19
NLBNPIT1YT19 20240621 52
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved